HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

Raily Aesthetic Medicine / Equity Capital Markets

On December 15th, <a href="https://www.smartkarma.com/entities/raily-aesthetic-medicine-international-holdings-limited" target="_blank" data-smartkarma-citation="entities:31100:1" rel="noopener">Raily Aesthetic Medicine (2135 HK)</a> began to raise capital by floating shares. The Company planned to issue 342.5 million shares at an issue price of HK$0.3-0.4 per share, with a corresponding market value of HK$617 million - HK$822 million. Raily is expected to go public on December 28th. Whether the Company could develop smoothly after going public is worth the attention of the capital market.

On December 15th, Raily Aesthetic Medicine (2135 HK) began to raise capital by floating shares. The Company planned to issue 342.5 million shares at an issue price of HK$0.3-0.4 per share, with a corresponding market value of HK$617 million - HK$822 million. Raily is expected to go public on December 28th. Whether the Company could develop smoothly after going public is worth the attention of the capital market. 

Pre-IPO Raily Aesthetic Medicine (2135.HK) - Here Are the Concerns

China

Raily Aesthetic Medicine International Holdings Limited is a medical aesthetics service provider in China, primarily in Zhejiang Province, offering cosmetic surgery, minimally invasive procedures, and skin rejuvenation. The company also provides management consulting and develops medical aesthetic devices and skincare products. It is headquartered in Hangzhou, Zhejiang, China, and was founded in 2018.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Pre-IPO Raily Aesthetic Medicine (2135.HK) - Here Are the Concerns

The article analyzed the major concerns of Raily Aesthetic Medicine in terms of financial position, high-quality talents, domestic regulations and...

Xinyao (Criss) Wang